NCT05696548 2026-04-09Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)National Cancer Center Hospital EastPhase 2 Active not recruiting51 enrolled
NCT04199104 2026-03-27A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)Merck Sharp & Dohme LLCPhase 3 Completed511 enrolled 20 charts